Yes my understanding is that biomarker is for selection but there is now a lot of thinking that reduction should also occur in not only amyloid but also PTau. So it may also be used as a scientific way to measure effectiveness. I do not think that is part of ACWs current interim trial though.
Ann: ACW June 2024 quarterly activity report & Appendix 4C, page-24
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
-0.001(4.00%) |
Mkt cap ! $70.68M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.5¢ | 2.4¢ | $31.50K | 1.295M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 3633200 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 3337059 | 6 |
View Market Depth
| Last trade - 15.17pm 31/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |